BCM
VNDA icon

BML Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

BML Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-228,500
Closed -$1.07M – 29
2024
Q3 		$1.07M Sell
228,500
-169,780
-43% -$910K 0.63% 19
2024
Q2 		$2.25M Buy
+398,280
New +$2.06M 1.61% 13

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

BML Capital Management's VNDA Position: Q4 2024 in Review

BML Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 228,500 shares — an estimated $1.07M sold.

BML Capital Management first reported a position in VNDA in Q2 2024 and held it in 2 quarters. The position peaked at $2.25M in Q2 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • BML Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • BML Capital Management sold 228,500 Vanda Pharmaceuticals shares in Q4 2024, an estimated $1.07M.
  • BML Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • BML Capital Management's Vanda Pharmaceuticals position peaked at $2.25M in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on BML Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.